About emici zuma b
Bispecific monoclonal antibody; clotting factor VIII mimetic
Used for
- Prevention of bleeding in hemophilia A with or without factor VIII inhibitors
Usual adult dose
Loading: 3 mg/kg under the skin weekly for four weeks. Then 1.5 mg/kg weekly, 3 mg/kg every two weeks, or 6 mg/kg every four weeks.
Usual dose in children
Same weight-based schedules as adults; used in children of all ages, including infants.
Common side effects
- Injection-site reactions
- Headache
- Joint pain
- Diarrhea
Important warnings
- Combining with activated prothrombin complex concentrate can cause serious blood clots or thrombotic microangiopathy.
- Breakthrough bleeding may still require treatment; follow specialist instructions.
- Do not use to treat an active bleeding episode.
Pregnancy
Human pregnancy data are limited; use only when a clinician determines it is needed.
Breastfeeding
It is unknown whether emicizumab passes into breast milk; discuss with a clinician.
Interactions
- Activated prothrombin complex concentrate: increased risk of blood clots and thrombotic microangiopathy.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.